Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Mar;22(3):284-292.
doi: 10.1016/j.jval.2018.10.004. Epub 2018 Nov 27.

Comparative Effectiveness of Computed Tomography- Versus Ultrasound-Guided Percutaneous Radiofrequency Ablation Among Medicare Patients 65 Years of Age or Older With Hepatocellular Carcinoma

Affiliations
Comparative Study

Comparative Effectiveness of Computed Tomography- Versus Ultrasound-Guided Percutaneous Radiofrequency Ablation Among Medicare Patients 65 Years of Age or Older With Hepatocellular Carcinoma

Jinhai Huo et al. Value Health. 2019 Mar.

Abstract

Background: For patients with hepatocellular carcinoma (HCC) not eligible for surgical resection, radiofrequency ablation (RFA) is a promising technique that reduces the risk of disease progression.

Objectives: To evaluate whether the trend of image guidance for RFA is moving toward the more expensive computed tomography (CT) technology and to determine the clinical benefits of CT guidance over the ultrasound (US) guidance.

Methods: A cohort of 463 patients was identified from the Surveillance, Epidemiology, and End Results and Medicare-linked database. The temporal trends in use of image guidance were assessed using the Cochrane-Armitage test. The associations between modality of image guidance and survival, complications, and costs were assessed using the Cox regression model, the logistic regression model, and the generalized linear model, respectively.

Results: The use of CT-guided RFA increased sharply, from 20.7% in 2002 to 75.9% in 2011. Compared with CT-guided RFA, those who received US-guided RFA had comparable risk of periprocedural and delayed postprocedural complications. Stratified analyses by tumor size also showed no statistically significant difference. In adjusted survival analysis, no statistically significant difference was observed in overall and cancer-specific survival. Nevertheless, the cost of CT-guided RFA ($2847) was higher than that of US-guided RFA ($1862).

Conclusions: Despite its rapid adoption over time, CT-guided RFA incurred higher procedural costs than US-guided RFA but did not significantly improve postprocedural complications and survival. Echoing the American Board of Internal Medicine's Choosing Wisely campaign and the American Society of Clinical Oncology's Value of Cancer Care initiative, findings from our study call for critical evaluation of whether CT-guided RFA provides high-value care for patients with HCC.

Keywords: HCC; RFA; costs; effectiveness; imaging.

PubMed Disclaimer

Conflict of interest statement

DECLARATION OF INTERESTS

We declare no competing interests.

Figures

Figure 1.
Figure 1.
Temporal trends in image guidance utilization (2002–2011). Figure 1 displays two trend lines for the use of CT-guided RFA (Solid line) and the use of US-guided RFA (Round dot line) from the year 2002 to 2011.
Figure 2.
Figure 2.
Overall survival and cancer-specific survival of patients undergoing radiofrequency ablation. Notes: the top panel (A) represents the overall survival; the bottom panel (B) represents the cancer-specific survival.
Figure 3.
Figure 3.
Adjusted odds ratios of use of image guidance on predicting postoperative complications. Notes: the top panel (A) represents the association of image guidance and periprocedural complications; the bottom panel (B) represents the association of image guidance and delayed complications.

Similar articles

Cited by

References

    1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005. J Clin Oncol. 2009; 27: 1485–91. - PMC - PubMed
    1. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go? Hepatology. 2014; 60: 1767–75. - PMC - PubMed
    1. American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society, 2018.
    1. White DL, Thrift AP, Kanwal F, et al. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017; 152: 812–20.e5. - PMC - PubMed
    1. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute; 2018.

Publication types

MeSH terms